NDAINJECTIONINJECTABLE
Approved
Nov 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
DRAXIMAGE MDP-25 (technetium tc 99m medronate) by Jubilant Therapeutics is clinical pharmacology when injected intravenously, technetium tc 99m medronate is rapidly cleared from the blood; about 50% of the dose is accumulated and retained by the skeleton, while the remaining 50% is excreted in the urine within 24 hours. Approved for prostate cancer, bone metastases. First approved in 1978.
Drug data last refreshed Yesterday
Mechanism of Action
CLINICAL PHARMACOLOGY When injected intravenously, Technetium Tc 99m Medronate is rapidly cleared from the blood; about 50% of the dose is accumulated and retained by the skeleton, while the remaining 50% is excreted in the urine within 24 hours. About 10% of the injected dose remains in the blood…
Indications (2)
Worked on DRAXIMAGE MDP-25 at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.